View Clinical Trial (Medical Research Study)
Physiologic Effects of Sleep Restriction
| City: |
|
Rochester |
| State: |
|
Minnesota |
| Zip Code: |
|
55905 |
| Conditions: |
|
Sleep Deprivation |
| Purpose: |
|
Evidence suggests a relationship between sleep deprivation and cardiovascular disease. The
investigators wish to determine whether 9 nights of modest sleep restriction results in
activation of cardiovascular disease mechanisms, thus potentially increasing the risk of
cardiovascular disease. The investigators hypothesize that sleep restriction will result in
elevated blood pressure, inflammation, and neurocognitive deficits.
|
| Study Summary: |
|
Evidence suggests a relationship between sleep deprivation and cardiovascular disease.
Voluntary sleep restriction is common, with 28% of the US adult population reports getting 6
or fewer hours of sleep per night, and those who do are 24% more likely to have
cardiovascular disease and have twice the risk of hypertension. Insufficient sleep may
conceivably be one of the most common, and most preventable, cardiovascular risk factors.
The investigators wish to determine whether 9 nights of modest sleep restriction results in
activation of cardiovascular disease mechanisms, thus potentially increasing the risk of
cardiovascular disease. The investigators will combine our cardiovascular studies with
state-of-the art sleep monitoring and neurocognitive tests to provide unambiguous data on
the neurologic effects of sleep restriction. Together, the investigators findings will help
explain whether the reduced sleep duration in the general population may be contributing to
the current epidemic of cardiovascular disease, and suggest strategies to reduce this risk.
|
| Criteria: |
|
Inclusion Criteria:
- Age 18-40 years
- No chronic medical conditions other than seasonal or environmental allergies
- On no prescription medications other than second generation antihistamines
(Cetirizine, Fexofenadine, Desloratadine, Loratadine, etc), oral contraceptive pills,
or intrauterine devices.
- BMI 18.5-35 kg/m2
- Both normotensive and prehypertensive people are eligible and will be studied
- Not a current smoker or tobacco user
- Not pregnant or breast feeding and not intending to become pregnant or breast feed
Exclusion Criteria:
- The investigators will exclude subjects who have any medical or psychiatric disorders
- History of anxiety or depression, and those taking any medications other than
non-sedating antihistamines or oral contraceptives.
- Those found to have depression on a depression screening tool (BDI-II) will be
excluded. Current smokers will be excluded.
- All female subjects will undergoing a screening pregnancy test and excluded if
positive.
- Subjects found to have significant sleep disorders will be excluded.
|
| NCT ID: |
|
NCT01433315 |
| Primary Contact: |
|
Principal Investigator
Virend K Somers, MD, PhD
Mayo Clinic
Diane E Davison, MA, RN
Phone: 507-255-8794
Email: davison.diane@mayo.edu
|
| Backup Contact: |
|
Email: calvin.andrew@mayo.edu
Andrew D Calvin, MD, MPH
Phone: 507-255-8794
|
| Location Contact: |
|
Rochester, Minnesota 55905
United States
Diane E Davison, MA, RN
Phone: 507-255-8794
Email: davison.diane@mayo.edu
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 22, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|